Screener
Exelixis EXEL Europe — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Exelixis’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0000939767-26-000098
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| U.S. | $578,361 | $524,768 | $1,136,907 | $1,041,952 |
| Europe | 46,007 | 37,033 | 85,575 | 69,739 |
| Japan | 4,322 | 6,460 | 17,020 | 12,017 |
| Total revenues | $628,690 | $568,261 | $1,239,502 | $1,123,708 |
Item 1. Financial Statements.
FAQ
- What is Exelixis's europe — total revenues?
- Exelixis (EXEL) reported europe — total revenues of $46.01M in Q2 2026.
- How has Exelixis's europe — total revenues changed year-over-year?
- Exelixis's europe — total revenues increased by 24.2% year-over-year, from $37.03M to $46.01M.
- What is the long-term trend for Exelixis's europe — total revenues?
- Over 4 years (2021 to 2025), Exelixis's europe — total revenues has grown at a -15.5% compound annual growth rate (CAGR), from $302.07M to $154.17M.
- What does europe — total revenues mean?
- This metric represents the total gross revenue generated from the sale of pharmaceutical products and licensing agreements within the European geographic market. It captures the financial performance of the company's oncology portfolio in this specific region, reflecting market penetration and commercial success of approved therapies. Fluctuations in this figure often indicate changes in regional regulatory approvals, competitive landscape shifts, or variations in local pricing and reimbursement agreements.
Ask your AI about Exelixis's europe — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude